Who Paid My Doc
Antonio Terrelonge
Family Medicine Miami, FL Medical Doctor
NPI 1386757102 CMS profile 1085928
1901 Nw 7Th St, Miami, FL 33125
General payments
$0
Research payments
$19,417
Ownership & investment interest
$0
Research they led as principal investigator
$3,195,394
Through program year 2021, Antonio Terrelonge of Miami, FL is reported in the CMS Open Payments database as having received $0 across 0 general payments and $19,417 in research payments paid to them. Separately, studies naming them as principal investigator received $3,195,394 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 98th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
2 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2021 | Research | $18,025 | 1 | |
| 2019 | Research | $1,392 | 12 |
Prescribing to Medicare patients
Part D · data year 2024 · 77 drugsPart D claims
2,811
Drug cost
$229,597
Branded share of claims
19.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Ozempic Semaglutide | Brand | 27 | $30,284 | |
| Farxiga Dapagliflozin Propanediol | Brand | 29 | $23,040 | |
| Eliquis Apixaban | Brand | 25 | $21,841 | |
| Xarelto Rivaroxaban | Brand | 25 | $17,035 | |
| Brilinta Ticagrelor | Brand | 29 | $15,587 | |
| Synjardy Empagliflozin/Metformin Hcl | Brand | 22 | $15,299 | |
| Linzess Linaclotide | Brand | 14 | $14,347 | |
| Trijardy Xr Empaglifloz/Linaglip/Metformin | Brand | 22 | $13,129 | |
| Jardiance Empagliflozin | Brand | 14 | $12,710 | |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | Brand | 14 | $10,439 |
The 10 drugs with the highest cost, of 77 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.
Records
13 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Family Medicine in Florida
Related records
Family Medicine in Florida
Practitioners in the same specialty and state, ranked by reported value.
All Family Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Florida
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.